🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. Tildacerfont/Placebo

    SPRUCE BIOSCIENCES, INC.

    Congenital Adrenal Hyperplasia

    phase 2 small molecule terminated

    2 trials

  2. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  3. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Nisotirotide, placebo to match LY, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  4. Tovinontrine, Tovinontrine, Tovinontrine, tovinontrine-matching placebo, immediate-release tablet

    Lacuna Pharma Pty Ltd

    Heart failure (HF) with reduced ejection fraction (HFrEF)

    phase 2 small molecule active

    1 trial

  5. Tozorakimab-placebo, Tozorakimab, SALBUTAMOL

    AstraZeneca AB

    Asthma

    phase 2 small molecule active

    1 trial

  6. TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  7. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial

  8. Tremelimumab placebo, concentrate for solution for infusion, Tremelimumab

    AstraZeneca AB

    unresectable pleural or peritoneal malignant mesothelioma

    phase 2 small molecule active

    1 trial

  9. Trontinemab, Placebo Trontinemab, Flortaucipir F18

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  10. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial

  11. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial

  12. VAY736, Placebo Solution for injection or infusion 0 mg/1 mL

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  13. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  14. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial

  15. VHB937, Placebo 00 mg/ 00mL, concentrate for solution for infusion (Placebo to VHB937)

    Novartis Pharmaceuticals

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  16. Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml

    Advanced Accelerator Applications

    Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

    phase 2 small molecule active

    1 trial

  17. Vi-Siblin S granulat, alli 60 mg hard capsules, Dietary fibre supplement Placebo - Maltodextrin

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  18. Vialed Saline Placebo, ALXN2030

    Alexion Europe SAS

    Antibody-Mediated Rejection after Kidney Transplantation

    phase 2 small molecule active

    1 trial

  19. Vipoglanstat, The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.

    Lacuna Pharma Pty Ltd

    Endometriosis related pain

    phase 2 small molecule active

    1 trial

  20. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial

  21. XB2001 or Placebo

    XBiotech Germany GmbH

    Pancreatic Cancer

    phase 2 mab active

    1 trial

  22. XEOMIN 100 unités, poudre pour solution injectable, Placebo of Xeomin 100 UI, powder for injection

    Pari Pharma GmbH

    Degenerative shoulder rotator cuff tendinopathy

    phase 2 small molecule active

    1 trial

  23. XPF-010, XPF-008, XEN1101 placebo

    Xenon Pharmaceuticals

    Adult focal (partial onset) epilepsy

    phase 2 small molecule active

    1 trial

  24. ZASOCITINIB, Matching Placebo for TAK-279

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources